Key Takeaways
- The 13Fs of David Tepper’s Appaloosa, Cathie Wood’s ARK and 32 other funds show third-quarter buys in software stocks such as CoreWeave, Oracle, Core Scientific, Akamai and ServiceNow.
- All five stocks have fallen since Sept. 30. CoreWeave is down 43% as investors question what it costs to fund its build-out.
- CoreWeave beat its own profit guidance last quarter, but consensus still expects negative free cash flow every year through 2030.
- CoreWeave needs cheaper money before it’s a buy. ServiceNow pays for its own growth and looks like the best of the five right now.
Plenty of big funds bought software stocks in the third quarter, and those stocks have been hammered since.
Their 13Fs for the quarter ended Sept. 30 show 34 funds buying or adding to software names, and David Tepper’s Appaloosa is one of them. The hardest hit is CoreWeave (CRWV), down 43% since Sept. 30. ServiceNow (NOW) is down 26%, Akamai (AKAM) 21%, Core Scientific (CORZ) 15% and Oracle (ORCL) 13%.
Tepper, Wood and Soros all went for CoreWeave
Appaloosa added 13% to its CoreWeave stake, bringing it to $106 million at Sept. 30, or 1.4% of its 13F stocks. It also opened a $172 million Oracle position. Cathie Wood’s ARK Invest added 58% to its stake, which reached $367 million. Soros Fund Management more than doubled its shares, though it also reported CoreWeave put options with $48 million of notional value.
The biggest bets went elsewhere. Pentwater Capital, which manages $19 billion, built its Oracle stake to $1.61 billion, or 12.3% of its 13F stocks. It also held Oracle puts with $656 million of notional value and calls with $323 million. Core Scientific is Clearline Capital’s largest holding, at 7.0% of its 13F stocks. Hawk Ridge Capital’s new ServiceNow stake is 5.0% of its own.
A 13F only shows what a fund held on Sept. 30, so we don’t know what any of them paid, or whether they still own the shares.
TIKR tracks 41 analysts on CoreWeave. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on CoreWeave, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See CoreWeave’s Analyst Ratings
CoreWeave still has to borrow to grow
CoreWeave’s customers keep signing, and its third-quarter adjusted operating income of $379 million beat the $200 million to $260 million it had guided to. Paying for the GPUs behind those contracts is the hard part. CoreWeave guided to $860 million to $940 million of interest expense for the same quarter. Consensus has its free cash flow negative every year through 2030 and its net debt climbing to $113.9 billion.
Its unsecured bonds fell below 80 cents on the dollar in mid-October. Management now expects its next contract-backed loan to price at a 7% to 7.5% yield. Then on Nov. 12, Jensen Huang resigned as NVIDIA’s CEO. NVIDIA supplies CoreWeave’s chips, owns its stock and rents back its capacity. Colette Kress, NVIDIA’s CFO and now its interim CEO, decides whether that support keeps coming.
Analysts have cut their average target since its August peak:

At $115, the average target is still 131% above the last close, but the lowest target is $39. Even at Sept. 30, before the drop, CoreWeave traded at 2.5x forward sales. That was its lowest quarter-end reading since its March 2025 IPO, against an average of 5.6x.
Oracle and Core Scientific ride the same build-out
Oracle carries a similar risk. S&P has said OpenAI accounts for about half of Oracle’s backlog, and OpenAI’s latest funding round has reached $15 billion, half its original target. Oracle trades at about 14x forward earnings. That’s inside the 12x to 17x range it held from 2014 to 2021, when its revenue grew about 1% a year. Its average target has come down hard over the past year:

Even at $236, it’s 98% above the last close.
Core Scientific is tied to CoreWeave directly. It leases about 590 megawatts to CoreWeave under contracts worth $10.2 billion, most of them for 12 years. Its total debt has roughly quadrupled since December, mostly through $3.3 billion of 7.75% secured notes. Analysts have barely moved their average target:

At $27, it’s double the last close.
ServiceNow and Akamai fell on their own reports
ServiceNow guided fourth-quarter cRPO growth to 18.5%, below the roughly 19.8% analysts expected. Its third-quarter operating margin of 32.5% still beat its 31% guide, and it raised its AI annual contract value target to $1.7 billion. Its average target has fallen from $231 to $156 in a year:

That’s still 57% above the last close. ServiceNow trades at about 22x forward earnings, against a five-year quarter-end average of 53x.
Akamai’s third-quarter revenue grew 6% to $1.12 billion, but its non-GAAP operating margin fell 6 points to 25%, and it cut its full-year revenue guidance. Its CEO bought $2.6 million of stock anyway. Akamai is also the only one of the five whose average target rose over the year:

At $129, it’s 53% above the last close.
I’d wait on CoreWeave
CoreWeave’s risk is plain: if new money keeps getting more expensive, the gains go to lenders and new shareholders. So I wouldn’t follow Tepper in yet.
If I could only buy one of the five right now, it’d be ServiceNow. It turned 34.9% of its 2025 revenue into free cash flow, so it pays for its own growth. It also trades at well under half its five-year average multiple.
Of course, CoreWeave could prove me wrong quickly. Watch the yield on its next contract-backed loan, NVIDIA’s first report under Kress, and these funds’ next 13Fs in mid-February.
So what is CoreWeave stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what CoreWeave could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!